---
title: "Danish Zealand's new drug trial results are positive, with better tolerance than GLP-1, potentially opening up a billion-dollar market!"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/206919357.md"
description: "Zealand's European stock price soared by 20%, reaching a historical high of 775 Danish krone at one point. Overnight, Zealand's American stock surged by 10% in the pink sheet market"
datetime: "2024-06-21T12:15:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/206919357.md)
  - [en](https://longbridge.com/en/news/206919357.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/206919357.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/206919357.md) | [繁體中文](https://longbridge.com/zh-HK/news/206919357.md)


# Danish Zealand's new drug trial results are positive, with better tolerance than GLP-1, potentially opening up a billion-dollar market!

GLP-1 class weight loss drug "formidable opponent" has arrived, and Amylin class drugs have emerged.

Danish pharmaceutical company Zealand Pharma announced positive trial results for its weight loss injection Petrelintide, triggering a strong market response. European stocks soared by 20% on Friday, reaching a historical high of 775 Danish kroner at one point. Overnight, Zealand's US stock market surged by 10%.

**Petrelintide belongs to the long-acting Amylin class of drugs, which have shown promising prospects in weight loss and stabilizing blood sugar. Zealand Pharma's success may position it as a strong competitor to GLP-1 drugs. Currently, Novo Nordisk and Eli Lilly have become the world's highest market value pharmaceutical companies with their popular GLP-1 drugs.**

Jefferies analysts pointed out:

> In addition to the effects of GLP-1, Amylin can also bring additional cardiovascular effects and may achieve higher quality weight loss by maintaining lean body weight. Based on these advantages, **sales of this drug are predicted to reach as high as $10 billion.**

The analysis indicates that Petrelintide not only achieves good weight loss effects but also has fewer side effects compared to GLP-1 drugs.

Jefferies analysts stated that despite 79% of the trial population being male (usually resulting in poorer weight loss effects with drugs) and with a lower median/mean baseline body mass index (BMI) (29kg/m²), significant weight loss effects were still achieved. This suggests that higher weight loss effects may be achieved when testing in a more balanced population.

**Furthermore, compared to GLP-1 drugs, Amylin drugs demonstrate good tolerability.** In the initial stages of treatment, they may cause milder gastrointestinal discomfort. During the weight maintenance phase, Amylin may help maintain weight by inducing a sense of fullness rather than food aversion caused by GLP-1 therapy, which could be crucial for long-term use and achieving higher quality, more sustainable weight loss effects.

A previous article pointed out that **results from Zealand's Phase 1B MAD trial showed that participants receiving high-dose Petrelintide treatment experienced an average weight loss of 8.6%, while the placebo group only had a weight loss of 1.7%.**

Zealand Pharma's Chief Medical Officer, Dr. David Kendall, stated:

```
These results further confirm the good tolerability of petrelintide and its potential to become an important alternative choice for GLP-1 class obesity management therapy.

The data paves the way for Petrelintide to quickly enter Phase 2b clinical trials, further demonstrating that this long-acting Amylin analog has comparable weight loss effects to GLP-1 receptor agonists and can provide a better patient experience. We look forward to initiating Phase 2b clinical trials of Petrelintide in the second half of 2024.
```

## 相关资讯与研究

- [5 Simple ETFs to Buy With $1,000 and Hold for a Lifetime](https://longbridge.com/zh-CN/news/281345615.md)
- [BUZZ-Rosenblatt says finding partner for Snap's smart glasses unit tough](https://longbridge.com/zh-CN/news/281357569.md)
- [BUZZ-Street View: Nike's turnaround remains work in progress](https://longbridge.com/zh-CN/news/281331333.md)
- [GRAPHIC-Apple's 50-year journey from garage to tech titan](https://longbridge.com/zh-CN/news/281342951.md)
- [3 Best Tech Stocks Rated 'Strong Buy' for April 2026: 50%+ Upside](https://longbridge.com/zh-CN/news/281347354.md)